Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Melevodopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK known ✓ | P06239 | 2/20 | 0.64 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.64 |
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.64 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.64 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.64 |
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.51 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.51 |
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.50 |
| ▸ | NR3C1 known ✓ | P04150 | 1/20 | 0.50 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.50 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.50 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.50 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.50 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.50 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.50 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.50 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.50 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.50 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.50 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Melevodopa SCHEMBL1149493 | 1.00 | ALOX15 (0.64) | ALOX15KDM4EHIF1AHSD17B10RECQL | |
| Melevodopa SCHEMBL29406901 | 1.00 | ALOX15 (0.64) | ALOX15KDM4EHIF1AHSD17B10RECQL | |
| Melevodopa SCHEMBL6825740 | 0.98 | ALOX15 (0.62) | ALOX15KDM4EHIF1AHSD17B10RECQL | |
| Melevodopa SCHEMBL29350486 | 0.98 | ALOX15 (0.66) | ALOX15KDM4EHIF1AHSD17B10RECQL | |
| Melevodopa SCHEMBL8470037 | 0.98 | ALOX15 (0.66) | ALOX15KDM4EHIF1AHSD17B10RECQL | |
| Melevodopa SCHEMBL27888379 | 0.98 | ALOX15 (0.66) | ALOX15KDM4EHIF1AHSD17B10RECQL | |
| Melevodopa SCHEMBL167562 | 0.98 | ALOX15 (0.66) | ALOX15KDM4EHIF1AHSD17B10RECQL | |
| Melevodopa SCHEMBL34004 | 0.98 | ALOX15 (0.66) | ALOX15KDM4EHIF1AHSD17B10RECQL | |
| Melevodopa SCHEMBL30064486 | 0.98 | ALOX15 (0.66) | ALOX15KDM4EHIF1AHSD17B10RECQL | |
| Melevodopa SCHEMBL17747950 | 0.97 | ALOX15 (0.64) | ALOX15KDM4EHIF1AHSD17B10RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927028-B2 | Pharmaceutical composition containing coated, floating particles | JAGOTEC AG (CH) | 2015-01-06 | — | — | US | claimed |
| CN-104098860-A | Preparation method for polyvinylidene fluoride/poly-dopamine-coated graphene nanocomposite | UNIV SICHUAN | 2014-10-15 | — | — | CN | claimed |
| EP-1382331-B1 | A pharmaceutical tablet characterized by showing a high volume increase when coming into contact with biological fluids | JAGOTEC AG (CH) | 2011-10-26 | — | — | EP | claimed |
| US-20080317841-A1 | Pharmaceutical Composition Containing Coated, Floating Particles | JAGOTEC AG (CH) | 2008-12-25 | — | — | US | claimed |
| US-20080020041-A1 | Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY | 2008-01-24 | — | — | US | claimed |
| EP-1835893-A1 | PHARMACEUTICAL COMPOSITION CONTAINING COATED, FLOATING PARTICLES | Jagotec AG (CH) | 2007-09-26 | — | — | EP | claimed |
| EP-1811975-A2 | ENTERIC COATED COMPOSITIONS THAT RELEASE ACTIVE INGREDIENT(S) IN GASTRIC FLUID AND INTESTINAL FLUID | The State of Oregon Acting by and (US) | 2007-08-01 | — | — | EP | claimed |
| WO-2006063858-A1 | PHARMACEUTICAL COMPOSITION CONTAINING COATED, FLOATING PARTICLES | JAGOTEC AG (CH) | 2006-06-22 | — | — | WO | claimed |
| WO-2006044202-A2 | ENTERIC COATED COMPOSITIONS THAT RELEASE ACTIVE INGREDIENT(S) IN GASTRIC FLUID AND INTESTINAL FLUID | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) | 2006-04-27 | — | — | WO | claimed |
| EP-0795324-B1 | A pharmaceutical tablet characterized by showing a high volume increase when coming into contact with biological fluids | JAGOTEC AG (CH) | 2004-04-21 | — | — | EP | claimed |
| EP-1382331-A1 | A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids | JAGOTEC AG (CH) | 2004-01-21 | — | — | EP | claimed |
| US-5780057-A | Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids | JAGOTEC AG (CH) | 1998-07-14 | — | — | US | claimed |
| EP-0795324-A2 | A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids | JAGOTEC AG (CH) | 1997-09-17 | — | — | EP | claimed |
| CN-1119434-A | Phenoxyphenylacetic acid derivatives | MERCK & CO INC (US) | 1996-03-27 | — | — | CN | claimed |
| US-4241082-A | 3,4-DIHYDROXYPHENYLALANINE OR DERIVATIVE THEREOF AS A DECARBOXYLASE INHIBITOR USED IN CONJUNCTION WITH AN AMINO ACID | SANKYO COMPANY LIMITED (JP) | 1980-12-23 | — | — | US | claimed |
| US-12533417-B2 | L-DOPA and/or DOPA decarboxylse inhibitors conjugated to sugar for the treatment of dopamine-responsive disorders | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2026-01-27 | — | — | US | disclosed |
| CN-119731370-A | Method and system for coating a drug container, cleaning a drug container and checking a drug container for particles and defects | 二氧化硅医疗产品公司 | 2025-03-28 | — | — | CN | disclosed |
| US-4035507-A | Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease | INTERX RESEARCH CORPORATION (US) | 1977-07-12 | — | — | US | disclosed |
| US-3998799-A | FOR TREATMENT OF PARKINSON'S DISEASE | INTERX RESEARCH CORPORATION (US) | 1976-12-21 | — | — | US | disclosed |
| US-3939253-A | Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease | INTERX RESEARCH CORPORATION (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533417-B2 | L-DOPA and/or DOPA decarboxylse inhibitors conjugated to sugar for the treatment of dopamine-responsive disorders | COMT, SLC6A3, DDT | LCK 2634/4885HTR2A 333/4885PTGS2 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.